Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide life sciences, nutraceuticals, cosmetics, food and beverage, and other key industries, will be presenting at the upcoming Development of a New Generation of Skincare Products webinar. The event, which is scheduled for Oct. 13, 2022, is sponsored by FORCE Family Office; the presentation will begin at noon ET. QVC icon, skincare visionary and anti-aging pioneer Adrienne Denese, MD, PhD, will be joining Pressure BioSciences for the presentation, which will focus on their partnership and the progress in developing a new generation of skincare products. Denese is president of Dr. Denese SkinScience, one of the most successful skincare lines in the country. The two companies are combining PBI’s revolutionary Ultra Shear Technology(TM) (“UST”) platform with Denese’s keen understanding of needs in the skincare market. “I am excited to partner with PBI as we together use the UST platform’s remarkable breakthrough in nanoemulsion effectiveness to develop a new generation of category-changing skincare products that will offer more effective absorption, bioavailability and therapeutic benefits to Dr. Denese SkinScience customers worldwide,” said Dr. Denese SkinSciences president Dr. Adrienne Denese, MD, PhD, in the press release.
To view the presentation, visit https://ibn.fm/vFBuf
To view the full press release, visit https://ibn.fm/6HHD0
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating, or pressure cycling technology (“PCT”) hydrostatic pressure. PCT is a patented-enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control biomolecular interactions (e.g., cell lysis, biomolecule extraction). The company’s primary focus is on the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged for the use of PBIO’s pressure-based technologies in the following areas: (1) the use of its recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room-temperature, stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information, visit the company website at www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
InvestorWire is part of the InvestorBrandNetwork.